Skip to content
Screener

MapLight Therapeutics, Inc. MPLT Balance Sheet Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$55.71M—$46.73M+22.2%$64.15M—————
$254.41M—$258.37M+266%$163.02M—————
$327.23M—$324.67M+183%$245.31M—————
$968K—$1.1M-9.3%$859K—————
$418.79M—$479.51M+250%$257.22M—————
$3.19M+404%$3.29M+72.0%$2.45M———-$1.05M—
$14.28M—$16.23M+1.9%$18.56M—————
$18.95M—$21.14M-2.7%$23.71M—————
$5K—$5K—$0—————
-$421.19M—-$360.52M-80.8%-$280.97M—————
$399.83M+285%$458.37M+337%-$274.18M-59.1%-$245.06M-58.8%-$215.83M-58.7%
$418.79M—$479.51M+250%$257.22M—————

FAQ

What are MapLight Therapeutics, Inc.'s total assets?
MapLight Therapeutics, Inc. (MPLT) holds $418.8M in total assets.
How much debt does MapLight Therapeutics, Inc. have?
MapLight Therapeutics, Inc. carries $5.6M in total debt against $399.8M of shareholders' equity, a debt-to-equity ratio of 0.01.
How much cash does MapLight Therapeutics, Inc. have?
MapLight Therapeutics, Inc. holds $55.7M in cash and equivalents.
Can MapLight Therapeutics, Inc. cover its short-term obligations?
Its current ratio is 22.91 — current assets exceed current liabilities.
Where does MapLight Therapeutics, Inc.'s balance sheet data come from?
Every line is extracted from MapLight Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.